|
1
|
Takei Y, Inoue K, Ogoshi M, Kawahara T,
Bannai H and Miyano S: Identification of novel adrenomedullin in
mammals: A potent cardiovascular and renal regulator. FEBS Lett.
556:53–58. 2004. View Article : Google Scholar
|
|
2
|
Taylor MM and Samson WK: Stress hormone
secretion is altered by central administration of
intermedin/adrenomedullin-2. Brain Res. 1045:199–205. 2005.
View Article : Google Scholar
|
|
3
|
Teng X, Song J, Zhang G, Cai Y, Yuan F, Du
J, Tang C and Qi YF: Inhibition of endoplasmic reticulum stress by
intermedin(1–53) protects against myocardial injury through a PI3
kinase-Akt signaling pathway. J Mol Med (Berl). 89:1195–1205. 2011.
View Article : Google Scholar
|
|
4
|
Tang B, Zhong Z, Shen HW, Wu HP, Xiang P
and Hu B: Intermedin as a prognostic factor for major adverse
cardiovascular events in patients with ST-segment elevation acute
myocardial infarction. Peptides. 58:98–102. 2014. View Article : Google Scholar
|
|
5
|
Yang SM, Liu J and Li CX: Intermedin
protects against myocardial ischemia-reperfusion injury in
hyperlipidemia rats. Genet Mol Res. 13:8309–8319. 2014. View Article : Google Scholar
|
|
6
|
Ni X, Zhang J, Tang CX and Qi YF:
Intermedin/adrenomedullin2: An autocrine/paracrine factor in
vascular homeostasis and disease. Sci China Life Sci. 57:781–789.
2014. View Article : Google Scholar
|
|
7
|
Bell D, Gordon BJ, Lavery A, Megaw K,
Kinney MO and Harbinson MT: Plasma levels of intermedin
(adrenomedullin-2) in healthy human volunteers and patients with
heart failure. Peptides. 76:19–29. 2016. View Article : Google Scholar
|
|
8
|
Lv Z, Wu K, Chen X, Zhang X and Hong B:
Plasma intermedin levels in patients with acute myocardial
infarction. Peptides. 43:121–125. 2013. View Article : Google Scholar
|
|
9
|
Zhang JS, Hou YL, Lu WW, Ni XQ, Lin F, Yu
YR, Tang CS and Qi YF: Intermedin1-53 protects against
myocardial fibrosis by inhibiting endoplasmic reticulum stress and
inflammation induced by homocysteine in apolipoprotein E-deficient
mice. J Atheroscler Thromb. 23:1294–1306. 2016. View Article : Google Scholar
|
|
10
|
Canova NK, Kmonickova E, Martinek J, Zidek
Z and Farghali H: Thapsigargin, a selective inhibitor of
sarco-endoplasmic reticulum Ca2+ -ATPases, modulates nitric oxide
production and cell death of primary rat hepatocytes in culture.
Cell Biol Toxicol. 23:337–354. 2007. View Article : Google Scholar
|
|
11
|
Chen G, Shen Y, Li X, Jiang Q, Cheng S, Gu
Y, Liu L and Cao Y: The endoplasmic reticulum stress inducer
thapsigargin enhances the toxicity of ZnO nanoparticles to
macrophages and macrophage-endothelial co-culture. Environ Toxicol
Pharmacol. 50:103–110. 2017. View Article : Google Scholar
|
|
12
|
Chen X, Zhang X, Gross S, Houser SR and
Soboloff J: Acetylation of SERCA2a, another target for heart
failure treatment? Circ Res. 124:1285–1287. 2019. View Article : Google Scholar
|
|
13
|
Prasad AM, Ma H, Sumbilla C, Lee DI, Klein
MG and Inesi G: Phenylephrine hypertrophy, Ca2+-ATPase
(SERCA2), and Ca2+ signaling in neonatal rat cardiac
myocytes. Am J Physiol Cell Physiol. 292:C2269–C2275. 2007.
View Article : Google Scholar
|
|
14
|
Liu M, Xue M, Wang XR, Tao TQ, Xu FF, Liu
XH and Shi DZ: Panax quinquefolium saponin attenuates cardiomyocyte
apoptosis induced by thapsigargin through inhibition of endoplasmic
reticulum stress. J Geriatr Cardiol. 12:540–546. 2015.
|
|
15
|
Adachi T: Modulation of vascular
sarco/endoplasmic reticulum calcium ATPase in cardiovascular
pathophysiology. Adv Pharmacol. 59:165–195. 2010. View Article : Google Scholar
|
|
16
|
Cook NL, Viola HM, Sharov VS, Hool LC,
Schoneich C and Davies MJ: Myeloperoxidase-derived oxidants inhibit
sarco/endoplasmic reticulum Ca2+-ATPase activity and perturb Ca2+
homeostasis in human coronary artery endothelial cells. Free Radic
Biol Med. 52:951–961. 2012. View Article : Google Scholar
|
|
17
|
Zhang C, Bose DD and Thomas DW:
Paradoxical effects of sarco/endoplasmic reticulum Ca(2+)-ATPase
(SERCA) activator gingerol on NG115-401L neuronal cells: Failure to
augment ER Ca(2+) uptake and protect against ER stress-induced cell
death. Eur J Pharmacol. 762:165–173. 2015. View Article : Google Scholar
|
|
18
|
Kranias EG and Hajjar RJ: Modulation of
cardiac contractility by the phospholamban/SERCA2a regulatome. Circ
Res. 110:1646–1660. 2012. View Article : Google Scholar
|
|
19
|
Gorski PA, Ceholski DK and Young HS:
Structure-function relationship of the SERCA pump and its
regulation by phospholamban and sarcolipin. Adv Exp Med Biol.
981:77–119. 2017. View Article : Google Scholar
|
|
20
|
Cerra MC and Imbrogno S: Phospholamban and
cardiac function: A comparative perspective in vertebrates. Acta
Physiol (Oxf). 205:9–25. 2012. View Article : Google Scholar
|
|
21
|
Xu J, Han Q, Shi H, Liu W, Chu T and Li H:
Role of PKA in the process of neonatal cardiomyocyte hypertrophy
induced by urotensin II. Int J Mol Med. 40:499–504. 2017.
View Article : Google Scholar
|
|
22
|
Ogden BE, Pang William W, Agui T and Lee
BH: Laboratory Animal Laws, Regulations, Guidelines and Standards
in China Mainland, Japan, and Korea. ILAR J. 57:301–311. 2016.
View Article : Google Scholar
|
|
23
|
Bian YF, Hao XY, Gao F, Yang HY, Zhang N
and Xiao CS: Adiponectin attenuates hypoxia/reoxygenation-induced
cardiomyocyte injury through inhibition of endoplasmic reticulum
stress. J Investiq Med. 59:921–925. 2011. View Article : Google Scholar
|
|
24
|
Sozen E, Karademir B and Ozer NK: Basic
mechanisms in endoplasmic reticulum stress andrelation to
cardiovascular diseases. Free Radic Biol Med. 78:30–41. 2015.
View Article : Google Scholar
|
|
25
|
Gustavsson M, Traaseth NJ, Karim CB,
Lockamy EL, Thomas DD and Veglia G: Lipid-mediated
folding/unfolding of phospholamban as a regulatory mechanism for
the sarcoplasmic reticulum Ca2+-ATPase. J Mol Biol. 408:755–765.
2011. View Article : Google Scholar
|
|
26
|
Periasamy M, Bhupathy P and Babu GJ:
Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression
and its relevance to cardiac muscle physiology and pathology.
Cardiovasc Res. 77:265–273. 2008. View Article : Google Scholar
|
|
27
|
Dickhout JG, Carlisle RE and Austin RC:
Interrelationship between cardiac hypertrophy, heart failure, and
chronic kidney disease: Endoplasmic reticulum stress as a mediator
of pathogenesis. Circ Res. 108:629–642. 2011. View Article : Google Scholar
|
|
28
|
Wang J, Hu X and Jiang H: ER
stress-induced apoptosis: A novel therapeutic target in myocardial
ischemia and reperfusion injury. Int J Cardiol. 214:233–234. 2016.
View Article : Google Scholar
|
|
29
|
Wang M, Meng XB, Yu YL, Sun GB, Xu XD,
Zhang XP, Dong X, Ye JX, Xu HB, Sun YF and Sun XB: Elatoside C
protects against hypoxia/reoxygenation-induced apoptosis in H9c2
cardiomyocytes through the reduction of endoplasmic reticulum
stress partially depending on STAT3 activation. Apoptosis.
19:1727–1735. 2014. View Article : Google Scholar
|
|
30
|
Hong J, Kim K, Kim JH and Park Y: The role
of endoplasmic reticulum stress in cardiovascular disease and
exercise. Int J Vasc Med. 2017:20492172017.
|
|
31
|
Li B, Yi P, Zhang B, Xu C, Liu Q, Pi Z, Xu
X, Chevet E and Liu J: Differences in endoplasmic reticulum stress
signalling kinetics determine cell survival outcome through
activation of MKP-1. Cell Signal. 23:35–45. 2011. View Article : Google Scholar
|
|
32
|
Chen H, Wang X, Tong M, Wu D, Wu S, Chen
J, Wang X, Wang X, Kang Y, Tang H, Tang C and Jiang W: Intermedin
suppresses pressure overload cardiac hypertrophy through activation
of autophagy. PLoS One. 8:e647572013. View Article : Google Scholar
|
|
33
|
Liu K, Deng X, Gong L, Chen X, Wang S,
Chen H, Chen X, Amrit B and He S: The effect of intermedin on
angiotensin II and endothelin-1 induced ventricular myocyte
hypertrophy in neonatal rat. Clin Lab. 59:589–596. 2013. View Article : Google Scholar
|
|
34
|
Hirose T, Totsune K, Mori N, Morimoto R,
Hashimoto M, Nakashige Y, Metoki H, Asayama K, Kikuya M, Ohkubo T,
et al: Increased expression of adrenomedullin 2/intermedin in rat
hearts with congestive heart failure. Eur J Heart Fail. 10:840–849.
2008. View Article : Google Scholar
|
|
35
|
Reddish FN, Miller CL, Gorkhali R and Yang
JJ: Calcium dynamics mediated by the endoplasmic/sarcoplasmic
reticulum and related diseases. Int J Mol Sci. 18:10242017.
View Article : Google Scholar
|
|
36
|
Chemaly ER, Troncone L and Lebeche D:
SERCA control of cell death and survival. Cell Calcium. 69:46–61.
2018. View Article : Google Scholar
|
|
37
|
Li L, Louch WE, Niederer SA, Aronsen JM,
Christensen G, Sejersted OM and Smith NP: Sodium accumulation in
SERCA knockout-induced heart failure. Biophys J. 102:2039–2048.
2012. View Article : Google Scholar
|
|
38
|
Roe AT, Ruud M, Espe EK, Manfra O,
Longobardi S, Aronsen JM, Norden ES, Husebye T, Kolstad TRS,
Cataliotti A, et al: Regional diastolic dysfunction in
post-infarction heart failure: Role of local mechanical load and
SERCA expression. Cardiovasc Res. 115:752–764. 2019. View Article : Google Scholar
|
|
39
|
Shi H, Han Q, Xu J, Liu W, Chu T and Zhao
L: Urotensin II induction of neonatal cardiomyocyte hypertrophy
involves the CaMKII/PLN/SERCA 2a signaling pathway. Gene. 583:8–14.
2016. View Article : Google Scholar
|
|
40
|
Kamiya T, Hara H and Adachi T: Effect of
endoplasmic reticulum (ER) stress inducer thapsigargin on the
expression of extracellular-superoxide dismutase in mouse 3T3-L1
adipocytes. J Clin Biochem Nutr. 52:101–105. 2013. View Article : Google Scholar
|
|
41
|
Lytton J, Westlin M and Hanley MR:
Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum
Ca-ATPase family of calcium pumps. J Biol Chem. 266:17067–17071.
1991.
|
|
42
|
Schmitt JP, Ahmad F, Lorenz K, Hein L,
Schulz S, Asahi M, Maclennan DH, Seidman CE, Seidman JG and Lohse
MJ: Alterations of phospholamban function can exhibit cardiotoxic
effects independent of excessive sarcoplasmic reticulum
Ca2+-ATPase inhibition. Circulation. 119:436–444. 2009.
View Article : Google Scholar
|
|
43
|
Bell D and McDermott BJ: Intermedin
(adrenomedullin-2): A novel counter-regulatory peptide in the
cardiovascular and renal systems. Br J Pharmacol. 153 (Suppl
1):S247–S262. 2008. View Article : Google Scholar
|
|
44
|
Lochner A and Moolman JA: The many faces
of H89: A review. Cardiovasc Drug Rev. 24:261–274. 2006. View Article : Google Scholar
|
|
45
|
Saad NS, Elnakish MT, Ahmed AAE and
Janssen PML: Protein kinase a as a promising target for heart
failure drug development. Arch Med Res. 49:530–537. 2018.
View Article : Google Scholar
|
|
46
|
Zhang X, Yuan Y, Jiang L, Zhang J, Gao J,
Shen Z, Zheng Y, Deng T, Yan H, Li W, et al: Endoplasmic reticulum
stress induced by tunicamycin and thapsigargin protects against
transient ischemic brain injury: Involvement of PARK2-dependent
mitophagy. Autophagy. 10:1801–1013. 2014. View Article : Google Scholar
|
|
47
|
Lindner P, Christensen B, Nissen P, Møller
JV and Engedal N: Cell death induced by the ER stressor
thapsigargin involves death receptor 5, a non-autophagic function
of MAP1LC3B, and distinct contributions from unfolded protein
response components. Cell Commun Signal. 18:122020. View Article : Google Scholar
|
|
48
|
Bhupathy P, Babu GJ and Periasamy M:
Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic
reticulum Ca2+ ATPase. J Mol Cell Cardiol. 42:903–911. 2007.
View Article : Google Scholar
|
|
49
|
Asahi M, Nakayama H, Tada M and Otsu K:
Regulation of sarco(endo)plasmic reticulum Ca2+ adenosine
triphosphatase by phospholamban and sarcolipin: Implication for
cardiac hypertrophy and failure. Trends Cardiovasc Med. 13:152–157.
2003. View Article : Google Scholar
|
